Skip to main navigation Skip to search Skip to main content

Metformin in tuberculosis: beyond control of hyperglycemia

Research output: Contribution to journalReview articlepeer-review

Abstract

Two global epidemics, diabetes mellitus (DM) and tuberculosis (TB), have converged making their control even more challenging. We herein have reviewed metformin’s (MTF) effect on patients with active and latent TB, as well as discussed its newly discovered biological mechanisms in mycobacteria. Mounting evidence suggests that MTF provides better outcomes in TB patients, especially those with DM. The mechanisms by which MTF produces its benefits are multiple. Though metformin’s potential has been proven in patients with DM, larger and more thorough clinical trials, in DM and non-DM-TB patients, need to be conducted. MTF could be added to the arsenal of anti-TB drugs, aiding in the goal of TB eradication worldwide.

Original languageEnglish
Pages (from-to)697-702
Number of pages6
JournalInfection
Volume47
Issue number5
DOIs
StatePublished - Oct 1 2019
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.

ASJC Scopus Subject Areas

  • Microbiology (medical)
  • Infectious Diseases

Keywords

  • Anti-tuberculous therapy
  • Diabetes
  • Metformin
  • Tuberculosis

Fingerprint

Dive into the research topics of 'Metformin in tuberculosis: beyond control of hyperglycemia'. Together they form a unique fingerprint.

Cite this